TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34528408
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI; 80 IU subcutaneously twice weekly on study days 1 and 4)
Study: 34528408
Drug: Synthetic ACTH1-24
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ACTH1-24 depot (1 mg subcutaneously twice weekly on study days 1 and 4)
Study: 34528408
Drug: Methylprednisolone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (32 mg orally once daily on study days 1 through 6)
Study: 35186225
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing during chemotherapy (CG)
Study: 33507984
Drug: Annual caries
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual caries preventive intervention including placement of fissure sealants, application of povidone-iodine and fluoride varnish, and standard diet and oral hygiene advice.
Study: 33139757
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Bifidobacterium-animalis-subsp.-Lactis 10×10^9 and Lactobacillus-Acidophilus 10×10^9 + 5 g of maltodextrin)
Study: 32649856
Drug: GRK5 variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRK5 variant (rs10886430-G)
Study: 32649856
Drug: G protein-coupled
Normalized name: G 1 (g protein-coupled estrogen receptor agonist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G protein-coupled receptor kinase 5 (GRK5)
Study: 35427476
Drug: DC371739 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC371739 + Atorvastatin
Study: 32709507
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 4 drops of 2% lavender essential oil with oxygen for 20 minutes
Study: 32709507
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of oxygen only
Study: 33067319
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg oral two times per day) plus avelumab (10 mg/kg intravenous every 2 weeks) in Cohort-1
Study: 33067319
Drug: Axitinib monotherapy
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib monotherapy in Cohort-2 (avelumab added after 6 weeks if corticosteroid dose could be tapered to ≤8 mg)
Study: 35394525
Drug: Positive STEPS
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Positive STEPS intervention (community health worker-led, 7-week duration, weekly telephone sessions, web-based videos, positive activities, wearable activity trackers)
Study: 33760027
Drug: edoxaban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban (oral factor Xa inhibitor)
Study: 32792320
Drug: L-thyroxine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (n = 40)
Study: 32311555
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular-Weight Heparin (LMWH) for 14 days in patients older than 70 years
Study: 32311555
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular-Weight Heparin (LMWH) in patients younger than 70 years
Study: 35961517
Drug: High-dose autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose autologous skeletal muscle-derived cells
Study: 35961517
Drug: Low-dose autologous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose autologous skeletal muscle-derived cells
Study: 35545584
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for 10 days
Study: 32171637
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids intervention (specific dosage and duration not mentioned)
Study: 35261299
Drug: Desogestrel (DSG)
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel (DSG) 0.075 mg
Study: 34269455
Drug: 450-ml blood
Normalized name: SUS SCROFA BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450-ml blood donation
Study: 36418502
Drug: Experimental desensitizing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental desensitizing gel (10% calcium gluconate, 0.1% dexamethasone acetate, 10% potassium nitrate, 5% glutaraldehyde) applied for 10 min before bleaching.
Study: 36418502
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied for 10 min before bleaching.
Study: 32347977
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 3 mg/d (immediate-release) at bedtime
Study: 35614395
Drug: Liberal Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal Fluid Infusion (LFI)
Study: 36180962
Drug: Blended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended therapy with therapeutic online intervention (TONI) containing 12 transdiagnostic online modules
Study: 35114141
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of QIV-HD and mRNA-1273 vaccine
Study: 35114141
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine alone
Study: 32228743
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with 0.5 g/day of SDR (SDR0.5)
Study: 32228743
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with 1 g/day of SDR (SDR1)
Study: 32228743
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with 1.5 g/day of SDR (SDR1.5)
Study: 35652829
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) ingestion (140 mL, ∼12.8 mmol of nitrate)
Study: 35652829
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) ingestion (140 mL)
Study: 32833791
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation treatment (n = 23)
Study: 32833791
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 26)
Study: 32277253
Drug: Thrombocytosis (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombocytosis (platelet count ≥ 400⋅10^9/L)
Study: 33008427
Drug: Ixazomib in
Normalized name: Product containing ixazomib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib in combination with cyclophosphamide and dexamethasone (ICD)
Study: 33008427
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from CD to ICD treatment
Study: 33158369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (alter treatment based on symptoms)
Study: 34137783
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use at study baseline
Study: 34686091
Drug: Dynamic stratified
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic stratified potassium supplementation (intermittent infusions of 30 mmol/100 mL potassium chloride)
Study: 34686091
Drug: Enteral potassium
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral potassium supplementation (10% potassium chloride administered orally in a bolus dose)
Study: 34686091
Drug: High intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intravenous potassium concentrations
Study: 33260139
Drug: L-Arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (6 g)
Study: 33166333
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (25OHD =20 ng/mL, vitamin D deficient)
Study: 33166333
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (>20 and <30 ng/mL, vitamin D insufficient)
Study: 33166333
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (25OHD =30 ng/mL, vitamin D sufficient)
Study: 34752902
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus placebo (n = 168)
Study: 34752902
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (n = 168)
Study: 32839195
Drug: Postangiography plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postangiography plasma kidney injury molecule‐1
Study: 32434204
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg upon admission followed by 40 mg/day)
Study: 32434204
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg upon admission followed by 20 mg/day)
Study: 32434204
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Rosuvastatin
Study: 35943822
Drug: Itraconazole monotherapy
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole monotherapy
Study: 35943822
Drug: Combined itraconazole/isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined itraconazole/isotretinoin therapy
Study: 32735335
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy-based group therapy program called Take a Breath, delivered via online videoconferences over 8 weeks (6 sessions).
Study: 32735335
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group receiving treatment as usual, offered the intervention 3 months after randomization.
Study: 36332661
Drug: Dextromethorphan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (loading dose 60 mg and two subsequent 30 mg doses at 2 and 5 hours after misoprostol administration)
Study: 36332661
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with usual-care nonsteroidal anti-inflammatory medications ± opioids
Study: 32142170
Drug: High atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High atorvastatin
Study: 32142170
Drug: Low atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low atorvastatin
Study: 35627597
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of Tetraselmis chuii (TC)
Study: 35627597
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of Tetraselmis chuii (TC)
Study: 35627597
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (200 mg/day of lactose powder)
Study: 34734030
Drug: LMWH-combination-prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH-combination-prophylaxis
Study: 32655024
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d nano-curcumin
Study: 33483443
Drug: YP Face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: YP Face IT (online psychotherapeutic intervention using social interaction skills training and cognitive-behavioural therapy)
Study: 35736001
Drug: 2-mg trametinib
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg trametinib containing 9% DMSO (test formulation)
Study: 35736001
Drug: 2-mg trametinib
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg trametinib containing 11% DMSO (reference formulation)
Study: 34510203
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice (WMJ) 500 mL daily for 2 weeks
Study: 33326122
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality rehabilitation system (30 minutes) + conventional occupational therapy (30 minutes)
Study: 33326122
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (60 minutes)
Study: 33743788
Drug: AOT-EXO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOT-EXO group (action observation treatment-based exoskeleton therapy)
Study: 33743788
Drug: EXO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXO group (exoskeleton therapy)
Study: 33743788
Drug: CT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT group (conventional therapy)
Study: 33377700
Drug: Paclitaxel liposome,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel liposome, 135 mg/m2, administered via intravenous drip for a course of 3 weeks, with 10 mg dexamethasone in 100 ml normal saline on the first day and metoclopramide and panxi tora azole on the second day.
Study: 33377700
Drug: Paclitaxel liposome
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel liposome treatment for bone metastasis and pain.
Study: 33377700
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival rate and median survival time after treatment.
Study: 33377700
Drug: Safety profile
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety profile of the treatment.
Study: 32969022
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) at a dose of 10 or 20 mg/kg/day for 14 weeks
Study: 35476887
Drug: Buprenorphine buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine buccal film (BBF) 300 mcg
Study: 35476887
Drug: Buprenorphine buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine buccal film (BBF) 600 mcg
Study: 35476887
Drug: Buprenorphine buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine buccal film (BBF) 900 mcg
Study: 35476887
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone 30 mg
Study: 35476887
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone 60 mg
Study: 36216006
Drug: Allopurinol (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (up-titrated to 600 mg daily, 300 mg daily for moderate renal impairment)
Study: 34607114
Drug: Selenised glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenised glucose (SeGlu) at 5 mg/kg
Study: 34607114
Drug: Selenised glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenised glucose (SeGlu) at 10 mg/kg
Study: 35092498
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg administered every second day for 4 weeks
Study: 35092498
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg administered every second day for 4 weeks
Study: 35092498
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg administered every second day for the second 4 weeks
Study: 35092498
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg administered every second day for the second 4 weeks
Study: 35092498
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg administered every second day for the first 4 weeks
Study: 35092498
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg administered every second day for the first 4 weeks
Study: 33818343
Drug: Control (waitlist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (waitlist, discussion group, or supportive therapy)
Study: 32853005
Drug: Clinician-Administered PTSD
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-Administered PTSD Scale (CAPS) with IRT estimation incorporating symptom weights and group-specific DIF
Study: 32853005
Drug: Clinician-Administered PTSD
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-Administered PTSD Scale (CAPS) with symptom counts
Study: 36130667
Drug: Norgestrel 0.075
Normalized name: norgestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 0.075 mg progestogen-only pill taken 6 hours late
Study: 36130667
Drug: Norgestrel 0.075
Normalized name: norgestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 0.075 mg progestogen-only pill missed completely
Study: 36130667
Drug: Norgestrel 0.075
Normalized name: norgestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 0.075 mg progestogen-only pill (both interventions)
Study: 35091325
Drug: Abatacept treatment
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept treatment for 48 weeks
Study: 32817078
Drug: LenMT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LenMT at 25 mg/day
Study: 32817078
Drug: LenMT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LenMT at 5 mg/day
Study: 32640130
Drug: Tofersen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofersen (20 mg)
Study: 32640130
Drug: Tofersen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofersen (40 mg)
Study: 32640130
Drug: Tofersen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofersen (60 mg)
Study: 32640130
Drug: Tofersen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofersen (100 mg)
Study: 33892777
Drug: 10 ?g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ?g lysergic acid diethylamide (LSD) orally every 3rd day for 6 weeks
Study: 38447622
Drug: Music Listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Listening (ML)
Study: 36220067
Drug: Single metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single metreleptin injection
Study: 34281695
Drug: G-ALP (crossed
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ALP (crossed screw fixation)
Study: 34281695
Drug: G-TRI (parallel
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-TRI (parallel screw fixation)
Study: 36342143
Drug: Baxdrostat 2
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 2 mg
Study: 36342143
Drug: Baxdrostat 1
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 1 mg
Study: 36342143
Drug: Baxdrostat 2
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 2 mg vs Placebo
Study: 36342143
Drug: Baxdrostat 1
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 1 mg vs Placebo
Study: 35236653
Drug: Gongning granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gongning granules plus low-dose hormone therapy
Study: 33248629
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet containing 300 mg/kg of medium-chain α-monoglycerides (MG)
Study: 36329915
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT) delivered via videoconference, 14 sessions over 16 weeks.
Study: 36329915
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group (no immediate treatment).
Study: 36329915
Drug: Internet-based CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based CBT (treatment group).
Study: 36329915
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group (after treatment).
Study: 33175090
Drug: Genetic liability
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic liability for increased prescription opioid use
Study: 33175090
Drug: Genetic liability
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic liability for increased prescription opioid use (multivariable MR)
Study: 32690503
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change physiotherapy intervention (six, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour approach discussion group)
Study: 32690503
Drug: Usual rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual rehabilitation (six, 30 min weekly group-based exercise sessions)
Study: 35955635
Drug: Short-wave diathermy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-wave diathermy heat therapy
Study: 35708106
Drug: LT4 administration
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 administration 3 hours post-iftar
Study: 35708106
Drug: LT4 administration
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 administration 1 hour pre-suhoor
Study: 35708106
Drug: LT4 administration
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 administration 30 minutes pre-iftar
Study: 36249792
Drug: Atovaquone 1500
Normalized name: ATOVAQUONE 1500 mg in 10 mL ORAL SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone 1500 mg BID
Study: 36273651
Drug: Adrenaline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (0.2 mg, 2 mL, 1:10000)
Study: 36273651
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (100 mg, 2 mL)